Compare KHC & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KHC | IQV |
|---|---|---|
| Founded | 1869 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9B | 36.4B |
| IPO Year | N/A | 2013 |
| Metric | KHC | IQV |
|---|---|---|
| Price | $25.46 | $230.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 17 |
| Target Price | $27.41 | ★ $236.71 |
| AVG Volume (30 Days) | ★ 17.2M | 1.4M |
| Earning Date | 10-29-2025 | 10-28-2025 |
| Dividend Yield | ★ 6.27% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.30 |
| Revenue | ★ $25,164,000,000.00 | $15,904,000,000.00 |
| Revenue This Year | N/A | $6.14 |
| Revenue Next Year | $0.08 | $5.28 |
| P/E Ratio | ★ N/A | $31.49 |
| Revenue Growth | N/A | ★ 3.85 |
| 52 Week Low | $23.70 | $134.65 |
| 52 Week High | $33.35 | $234.30 |
| Indicator | KHC | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 68.05 |
| Support Level | $24.37 | $228.69 |
| Resistance Level | $25.77 | $234.30 |
| Average True Range (ATR) | 0.44 | 5.76 |
| MACD | 0.15 | 0.89 |
| Stochastic Oscillator | 82.44 | 83.07 |
In July 2015, Kraft merged with Heinz to create one of North America's largest food and beverage manufacturers. However, the firm now intends to split its global sauces arm from its North American grocery segment in the second half of 2026. Beyond its namesake brands, its portfolio includes Oscar Mayer, Velveeta, and Philadelphia. While the retail channel drives around 85% of its total sales, the firm also maintains a growing foodservice presence. Outside North America, Kraft Heinz's global reach encompasses a distribution network in Europe and emerging markets, which accounts for nearly 25% of its consolidated sales base. The company's products are sold in more than 190 countries and territories.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.